Icagen, Inc. achieved positive results from a Phase IIa study of senicapoc in allergic asthma. Senicapoc reduced the late asthmatic response (LAR) to a challenge of inhaled allergen, the primary endpoint of the study, determined by the decline in FEV1, the volume of air that can be forcibly exhaled in one second. The improvement in the average decline in FEV1 was 29%, in the maximum decline 18%, and in the area under the curve 28% of FEV1. Patients receiving senicapoc demonstrated an improvement...